Article Text

Download PDFPDF
Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’
  1. Tomoyuki Kawada
  1. Hygiene and Public Health, Nippon Medical School, Bunkyo-ku 1138602, Japan
  1. Correspondence to Dr Tomoyuki Kawada, Hygiene and Public Health, Nippon Medical School, Bunkyo-ku 1138602, Japan; kawada{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

I read with great interest the paper by Scarsi et al. 1 The authors examined the effect of colchicine (1 mg/day) in patients with COVID-19 by setting standard of care (hydroxychloroquine, and/or intravenous dexamethasone, and/or lopinavir/ritonavir).1 The adjusted HR (95% CI) of colchicine for mortality was 0.151 (0.062–0.368). In contrast, older age, worse PaO2/FiO2 and higher serum levels of ferritin at entry were no risk factors of mortality. The authors recommended controlled clinical trials to verify efficacy and safety, and I …

View Full Text


  • Contributors The author presented the recent information on the association between colchicine and COVID-19.

  • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles